CD14 and infarction: Additionally, in vivo studies in mouse models of AMI found an increase in the expression of CX3CL1 during phase 2 of infarction, which suggested the mobilization of Ly-6Clow monocytes (mouse counterparts of human CD14++CD16+/CD14+CD16++ monocytes) [4, 6].